RNS Number : 5814W
Coiled Therapeutics PLC
28 September 2026

28 September 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

Director/PDMR Shareholding

Coiled Therapeutics (AIM: COIL / OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, advises that Stephen West, Non-Executive Director, has today purchased ordinary shares of £0.01 each in the Company ("Ordinary Shares"), as detailed below:

Number of Ordinary Shares Acquired	Average Price Paid per Ordinary Share	Total Consideration Paid (including charges)	Number of Ordinary Shares Now Held	% of Company's Issued Capital
531,743	7.52 pence	£40,016.77	2,700,368	0.63%

Regulatory Information

This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").

-ENDS-

Enquiries:

Coiled Therapeutics plc — Via Burson Buchanan
Sotirios Stergiopoulos (Chairman)
Sridhar Vempati (CEO)

SP Angel Corporate Finance LLP (Nominated Adviser & Joint Broker) — +44 (0)20 3470 0470
David Hignell / Adam Cowl / Devik Mehta (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)

Shore Capital Stockbrokers Limited (Joint Broker) — +44 (0)20 7408 4090
David Coaten / Sophie Collins

CPS Capital Group Pty Ltd (Joint Broker) — +61 (0)8 9223 2222
Jason Peterson / David Valentino

Burson Buchanan (Public Relations) — +44 (0)20 7466 5000
Henry Harrison Topham / Jamie Hooper / Toto Berger

Harbor Access (US Investor Relations) — +1 475 477 9404
Matt Kelly / Jonathan Paterson

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage precision oncology company advancing first-in-class small molecule therapies targeting validated cancer dependencies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently being evaluated in an ongoing Phase I clinical trial

in the U.S. (ClinicalTrials.gov ID: NCT06136884). The Company's clinical development strategy focuses on generating evidence in selected tumour types, including ovarian and prostate cancer, to support potential pharmaceutical partnerships. Its broader pipeline includes a STAT-6 siRNA programme for immunology indications.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule designed to selectively inhibit Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 has emerged as a validated cancer dependency across multiple aggressive solid tumours and is largely dispensable in normal adult cells, supporting the potential for a broad therapeutic window.

By disrupting TACC3-driven protein interactions, AO-252 induces mitotic and replication stress, impairs DNA damage repair and promotes cancer cell death. Its ability to cross the blood-brain barrier is a key differentiator, supporting its potential to treat both primary brain tumours and brain metastases.

The Company is currently enrolling patients in dose-escalation cohorts evaluating the new lipid-based softgel formulation of AO-252. Phase I/II dose-expansion cohorts in ovarian and prostate cancer are planned to follow once the optimal dose has been established.

For more information, please visit: www.coiledplc.com and follow us on LinkedIn.

The notification below, made in accordance with the requirements of the UK MAR, provides further detail:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	**Details of the person discharging managerial responsibilities / person closely associated**		
a)	Name	Stephen West	
2	**Reason for the notification**		
a)	Position/status	Non-Executive Director	
b)	Initial notification /Amendment	Initial	
3	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**		
a)	Name	Coiled Therapeutics plc	
b)	LEI	254900P4SISIWOR9RH34	
4	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**		
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.01 par value ISIN: GB00BSHRN331	
b)	Nature of the transaction	Purchase of 531,743 Ordinary Shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		7.399 pence per share 7.650 pence per share	270,306 261,437
d	Aggregated information - Aggregated volume - Price	- 531,743 - 7.52p	
e)	Date of the transactions	28 September 2026	

f)	Place of the transactions	London Stock Exchange (XLON); AIM

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHKVLBLQKLXBBF